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Abstract
The human commensal pathogen, Streptococcus pneumoniae, expresses a number of virulence 
factors that promote serious pneumococcal diseases, resulting in significant morbidity and 
mortality worldwide. These virulence factors may give S. pneumoniae the capacity to escape 
immune defenses, resist antimicrobial agents, or a combination of both. Virulence factors also 
present possible points of therapeutic intervention. The activities of the surface endonuclease, 
EndA, allow S. pneumoniae to establish invasive pneumococcal infection. EndA’s role in DNA 
uptake during transformation contributes to gene transfer and genetic diversitifcation. Moreover, 
EndA’s nuclease activity degrades the DNA backbone of neutrophil extracellular traps (NETs), 
allowing pneumococcus to escape host immune responses. Given its potential impact on 
pneumococcal pathogenicity, EndA is an attractive target for novel antimicrobial therapy. Herein, 
we describe the development of a high-throughput screening assay for the discovery of nuclease 
inhibitors. Nuclease-mediated digestion of double-stranded DNA was assessed using fluorescence 
intensity changes of the DNA dye ligand, PicoGreen. Under optimized conditions, the assay 
provided robust and reproducible activity data (Z'=0.87) and was used to screen 4727 small 
molecules against an imidazole-rescued variant of EndA. In total, 10 small molecules were 
confirmed as novel EndA inhibitors that may have utility as research tools for understanding 
pneumococcal pathogenesis, and ultimately drug discovery.
Keywords
Streptococcus pneumoniae; EndA; endonuclease; virulence factor; high-throughput screening 
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INTRODUCTION
Streptococcus pneumoniae (pneumococcus) is an asymptomatic colonizer of the human 
upper respiratory tract. However, the commensal bacteria is also the causative agent of 
respiratory and life-threatening invasive diseases. Dissemination of pneumococci from the 
nasopharynx into the lungs or bloodstream leads to otitis media, pneumonia, bacteraemia 
and meningitis.1 Pneumococcal diseases are traditionally treated with antibiotics and 
prevented with polysaccharide-protein conjugate vaccines. Unfortunately, due to the 
dramatic increase in antibiotic resistance and limitations of the currently available vaccines, 
the threat from pneumococcal disease remains high. Thus, therapeutics directed against 
novel S. pneumoniae targets are needed to combat pneumococcal infections.
S. pneumoniae pathogenesis is a complex and dynamic process. The human host 
continuously deploys an array of innate and acquired immune defenses to prevent 
pneumococci from traversing epithelial barriers.2 However, the pathogen expresses 
numerous virulence factors, which can act alone or in concert to promote invasive 
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pneumococcal disease. The major virulence attribute of pneumococcus is the presence of a 
thick, capsular polysaccharide layer, which inhibits phagocytosis and complement 
recognition.3, 4 In addition to the capsule, there are many other pneumococcal virulence 
factors that are involved in the disease process. Elucidating the roles played by virulence 
factors allows an understanding of the pathogenesis of infection and can provide insights 
into novel therapeutic options.
The presence of a surface nuclease involved in pneumococcal DNA transport was reported 
over 40 years ago.5 S. pneumoniae is naturally transformable and the nuclease activity of 
EndA is necessary for non-transforming strand degradation and DNA uptake.6 EndA is 
required for efficient bacterial transformation in pneumococcus; strains with deactivating 
endA mutations exhibit an efficiency of transformation reduced more than 100-fold 
compared to wild type.7–9 Through its role in DNA uptake, EndA contributes to genetic 
plasticity, a defining characteristic of the pathogen.10 This flexibility of pneumococcus 
likely facilitates responses to evolutionary pressures that provide a significant advantage 
during infection, such as evasion of host immune defenses or development of antibiotic 
resistance.11
The ability of neutrophils to clear invading microorganisms by phagocytosis is well 
established. Recently, neutrophils have been shown to produce neutrophil extracellular traps 
(NETs) that entrap and kill pathogens in the extracellular environment.12 NETs consist of 
neutrophil DNA as a backbone with embedded antimicrobial peptides, histones and 
proteases. The web-like structure of NETs physically trap bacteria, but unlike Shigella and 
other pathogens,13 the pneumococcus is relatively resistant to NET-mediated killing.14 
While not killed by NET constituents, pneumococcus entrapment by NETs impedes 
bacterial dissemination. However, the surface endonuclease, EndA, facilitates pneumococcal 
escape by degrading the DNA scaffolding of the NETs.15 Mutant S. pneumoniae strains 
lacking EndA activity do not destroy NETs and show decreased virulence in mouse models 
of infection.15
EndA’s importance for S. pneumoniae pathogenesis arises from its cardinal roles in 
transformation and facilitating NET escape. Deletion of endA diminishes the efficiency of 
transformation, which could hinder the genetic variation that contributes to pneumococcal 
virulence. Moreover, pneumococci lacking endA are not able to free themselves from NETs 
and show reduced invasive infection in mice. Given this evidence, we hypothesize that 
small-molecule inhibition of EndA could attenuate pneumococcal pathogenesis and offer a 
novel target for the control of pneumococcal infection. The discovery of potent and selective 
EndA inhibitors that modulate the target in bacteriological studies and mouse models of 
pneumococcal infection would be an important step in elucidating EndA’s role in the 
pathogenesis of S. pneumoniae.
In this study, we sought to develop a simple, inexpensive, and robust high-throughput 
screening (HTS) assay that directly targeted EndA and its catalytic hydrolysis of double-
stranded DNA (dsDNA). The use of the DNA dye ligand, PicoGreen, to monitor nuclease 
activity in real-time had been reported previously.16 We adapted this approach for HTS with 
EndA. Following optimization and validation, the PicoGreen nuclease assay was used to 
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screen 4,727 compounds for EndA inhibitors. This initial screen identified 10 validated hit 
compounds, and subsequent assays and counterscreens led to an EndA inhibitor with 
potential for further study and optimization. This work is a promising start for structure-
based drug design using hits reported herein, in concert with additional screening efforts to 
discover novel EndA inhibitors.
MATERIALS AND METHODS
Materials
The Quant-it™ PicoGreen dsDNA Reagent (Cat. No. P7581) was purchased from Molecular 
Probes by Life Technologies (Grand Island, NY). Lambda DNA-Hind III digest (Cat. No. 
N3012L) was purchased from New England Biolabs (Ipswich, MA). The cloning, 
production, and purification of EndA(H160G) were reported previously.17 Unless otherwise 
stated, all other reagents used for buffers and assays were purchased from Thermo Fisher 
Scientific (Waltham, MA).
LOPAC Compound Collection
The Library of Pharmacologically Active Compounds (LOPAC) was purchased from 
Sigma-Aldrich as 10 mM stocks in DMSO. The library was previously prepared as 1 µL 
samples in 384-well V-bottom polypropylene microplates (Greiner, Monroe, NC), sealed by 
a ALPS 3000 microplate heat sealer (Thermo Fisher Scientific) and stored at −20 °C. On the 
day of use, the compounds were thawed and diluted to 100 µM (10× final concentration) in 
R Buffer (Reaction Buffer: 25 mM imidazole, 20 mM Tris-HCl pH 8.0, 10 mM sodium 
acetate, 10 mM MES, 25 mM NaCl, 5 mM MgCl2, 1.5 µM BSA, and 0.01% v/v Triton 
X-100) over 2 steps using a Thermo Fisher Scientific Multidrop Combi Reagent Dispenser 
and Multimek NSX-1536 assay workstation system fitted with a 384-well head 
(Nanoscreen, Charleston, SC). Finally, 1 µL of this stock was spotted into the wells of a 
384-well black PerkinElmer Proxiplate (Waltham, MA) for assay use, as described below.
Kinase Focus Set
The Kinase Focus Set was designed and purchased by the Center for Integrative Chemical 
Biology and Drug Discovery (CICBDD). Design of this library was based on selection from 
vendor kinase-directed sets. Initially, more than 100K compounds were received from 
various vendors, in the form of SD files. The vendors had originally designed these kinase-
focused libraries using one or more of the following approaches: (1) searching virtual and 
physical general purpose libraries for compounds similar to known kinase inhibitors; (2) 
selecting or synthesizing compounds having a hinge-binding motif; i.e., adenosine 
bioisosters with a high likelihood to bind the backbone in the kinase hinge-binding motif 
conserved in every kinase structure; and (3) structure- or ligand-based virtual screening on 
representative kinase structures. In order to reduce the size of the library, while preserving 
its efficiency in screening, we removed structural duplicates, filtered out compounds that did 
not satisfy the “rule-of-five”18 and, finally, performed a cluster-based selection. Clustering 
was performed by means of the Pipeline Pilot software (Pipeline Pilot, v. 8.5, Accelrys 
Software Inc., 2011) in such a way that compounds belonging to the same cluster had 
pairwise similarity of 50% or more (according to Tanimoto metrics with ECFP4 
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descriptors). Once clustered, we selected 3 to 10 representative compounds, depending on 
the cluster size. In the end, the CICBDD acquired 4,727 representative compounds that 
constitute the Kinase Focus Set.
The compound plates of the Kinase Focus Set were prepared by resuspending the powder 
stock to 1 mM in 100% DMSO in barcoded glass vials with sonication using a Covaris S2 
sonicator (Covaris, Woburn, MA). Compounds were plated at 1 mM in 100% DMSO in 
384-well V-bottom polypropylene microplates using a Tecan Genesis 200 (Münnedorf, 
Switzerland). A Multimek spotted 1 µL of the 1 mM compounds into 384-well V-bottom 
polypropylene microplates and plates were heat sealed and stored at −20 °C. During 
screening, these previously prepared plates were thawed and diluted to 100 µM by a single 
addition of R Buffer, and 1 µL of this stock was spotted into the wells of a 384-well 
Proxiplate.
PicoGreen Nuclease Assay
The assay was performed by using a Multidrop dispenser to add 1 µL of 10% (v/v) DMSO 
in the left two columns (columns 1, 2) for the positive control reactions. In the right two 
columns (columns 23, 24), 1 µL of 500 mM EDTA was spotted for the negative control 
reactions. Assay reactions were carried out directly in the Proxiplate wells containing 1 µL 
compounds or controls. The reaction volume in each well was 10 µL, and final 
concentrations of compound and DMSO were 10 µM and 1% (v/v), respectively. A 2× 
solution of EndA(H160G), containing 30 nM EndA, was prepared in R Buffer. To all wells 
of the assay plates, 4.5 µL of the 2× EndA(H160G) in R Buffer was added using a Multidrop 
dispenser. EndA was allowed to pre-incubate with compounds and controls for 20 min in a 
37 °C air incubator. Following pre-incubation, a 2× solution of lambda DNA-Hind III digest 
(2 µg/mL) in R Buffer was added at a volume of 4.5 µL to each well. Reaction time began 
immediately upon addition of the dsDNA substrate and was allowed to proceed for 30 min 
at room temperature. The plates were quenched by adding 10 µL of 2× PicoGreen Reagent 
(1.6 µM or 1/200 dilution) in Q Buffer (Quench Buffer: 10 mM Tris-HCl pH 8.0, 20 mM 
EDTA) to each well. Plates were incubated at ambient temperature in the dark for 5 min 
prior to reading on an EnVision Multilabel Reader (PerkinElmer) using excitation 
wavelength of 480 nm and emission wavelength of 520 nm.
Compounds being evaluated for dose-response runs were attained from frozen 10 mM 
stocks in 100% DMSO. The Kinase Focus Set hits were plated as 3-fold dilutions over 10 
points using the Tecan in 384-well V-bottom polypropylene microplates. The dose-response 
curves for LOPAC hits were prepared as 3-fold dilutions over 10 points using a multi-
channel pipette. Compound titration series of all hits for IC50 evaluation were spotted at 1 
µL by a Multimek instrument into 384-well V-bottom microplates and diluted 10-fold in R 
Buffer using a Multidrop dispenser. The diluted titrations were then spotted at 1 µL into 
384-well black Proxiplates (Perkin Elmer) in duplicate, and reagents were added to initiate 
the assay as described above. The final top concentration of dose-response curves was 30 
µM compound (1% v/v DMSO).
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The fluorescence intensity count of each well was measured using excitation wavelength of 
480 nm and emission wavelength of 520 nm on the EnVision plate reader. Screening data 
was processed using ScreenAble software (Screenable Solutions). The percent inhibition 
was determined on a plate-to-plate basis by comparing the fluorescence intensity count per 
compound well (F) with the plate-averaged control wells (n = 32 for each control), using the 
following relationship:
where μmin and μmax are the plate-averages of the minimum signal (maximum EndA 
activity, 1% v/v DMSO added) and maximum signal (inhibited, 50 mM EDTA added) 
controls, respectively.
The Z′ statistical parameter was calculated for each assay plate to assess the quality and 
robustness of the HTS. Z′ factor was determined using the following formula:
where σmax and σmin are standard deviations in respective plate maximum and minimum 
signal controls, and μmax and μmin are the plate-averages of the respective controls, as 
defined above.
Compound IC50 values were calculated by first converting the FI count to percent inhibition 
with respect to on-plate controls and then fitting the percent inhibition values to curve 
equations using ScreenAble or Prism (GraphPad Software, San Diego, CA). The IC50 values 
of the Kinase Focus Set hits were calculated using ScreenAble with a 3- or 4-parameter 
curve fit. The LOPAC hits were analyzed in Prism using a one-site specific binding with 
Hill slope and Bmin.
Plasmid DNA conversion assay
EndA was diluted stepwise to 100 pM in activity buffer (20 mM Tris-HCl pH 8.0, 5 mM 
MgCl2, 50 mM imidazole) and incubated with 15 ng/ml of supercoiled pBluescript II SK(+) 
plasmid (Stratagene), in the presence of DMSO or inhibitor. At scheduled timepoints, the 
reactions were quenched by addition of loading dye containing EDTA (250 mM). Reaction 
products were separated by electrophoresis on an agarose-TBE gel (0.8 % w/v). DNA 
species in the gel were visualized by ethidum bromide staining and scanned with the Gene 
Genius Bio imaging system (Syngene).
Real-time PicoGreen nuclease assay
All reactions were carried out in 96-well plates (Corning 3991 black flat-bottom) at 25°C 
inside the POLARstar Ultima plate reader (BMG labtech). Fluorescent intensity counts were 
recorded at excitation wavelenth, 480 nm, and emission wavelength, 520 nm. Reaction 
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mixtures (100 µl) consisted of 5 µL of 100% DMSO or 20× inhibitor in 100% DMSO and 
90 µl of 16.6 nM EndA(H160G) in RT buffer (Real-time buffer: 25 mM imidazole, 20 mM 
Tris-HCl pH 8.0, 10 mM sodium acetate, 10 mM MES, 25 mM NaCl, 5 mM MgCl). 
Reaction was initialized by addition of 5 µl of 20× lambda DNA-Hind III digest (1 µg/mL 
final) and 20× PicoGreen (0.3 µM final) in RT buffer. After initialization, shaking for 30 
seconds mixed the plate and plate data recorded every 1 min for 70 min. Initial velocities 
were calculated and used in further analysis. The counter-screen assay was conducted 
following the same protocol used in the Real-time PicoGreen nuclease assay excluding 
EndA(H160G). In detail, inhibitors were diluted to 20× concentrations (1, 30, 100 µM final) 
in 100% DMSO and 5 µL was added to each well followed by 95 µL of lambda DNA-Hind 
III digest (1.5 µM final) and PicoGreen (0.3 µM final). The fluorescent intensity counts were 
recorded and averaged over 10–15 min for use in further analysis. The rapid-dilution assay 
was also performed using the Real-time PicoGreen nuclease assay with EndA(H160G) pre-
incubated with a high concentration of inhibitor. Specifically, 2 µL of a solution of 1 µM 
EndA mixed with 90 µM inhibitor for 20 min at room temperature was diluted into 95 µl of 
RT buffer. Reaction was started with 5 µL addition of 20× lambda DNA-Hind III digest (1 
µg/mL final) and 20× PicoGreen (0.3 µM final) in RT buffer and proceeded as described 
above for the Real-time PicoGreen nuclease assay.
RESULTS AND DISCUSSION
Assay development and validation
Our main objective in developing a high-throughput screening assay for EndA nuclease 
activity was to identify selective chemical probes that would enhance our understanding of 
EndA’s role in pneumococcal virulence. However, we were confronted with a challenge 
given the lack of HTS-compatible methods for detecting nuclease activity. Traditional 
nuclease activity methods such as viscometry,19 gel electrophoresis,20 and assays using 
radioactive or fluorescent-labeled DNA susbstrates21 are time-consuming, laborious and can 
be very expensive. In comparison, a label-free fluorescent nuclease assay would be 
continuous, convenient, and HTS conducive.16, 22 Here, we developed and optimized an 
EndA nuclease assay using the fluorescent dye ligand, PicoGreen. We also assessed the 
robustness, reproducibility, and HTS compatibility of the PicoGreen assay to ensure its 
success in screening diverse drug-like small molecules for the inhibition of EndA.
The use of fluorescent DNA dye provides both a precise and cost-efficient method of 
monitoring nuclease activity in vitro. PicoGreen is a sensitive fluorescent dye widely used in 
analytical protocols in which double-stranded DNA (dsDNA) detection is needed.23 
PicoGreen associates with dsDNA through intercalation, minor-groove binding, and 
electrostatic interactions,24 resulting in a significant increase in fluorescence, compared to 
free dye in solution. During reaction with EndA, the dsDNA is cleaved into small fragments, 
which have a weakened interaction with PicoGreen, resulting in lower fluorescence (Fig. 1). 
In contrast, reactions in the presence of EndA inhibitors should retain full-length dsDNA 
substrate and result in strong fluorescent signal upon addition of PicoGreen.
Standard fluorescence versus DNA concentration curves using several dsDNA substrates 
with 0.8 µM PicoGreen were produced. Comparing the standard curves for calf thymus 
Peterson et al. Page 7













DNA, salmon testes DNA, and lambda DNA digested with Hind III, we selected the latter as 
our substrate. The standard curve of lambda DNA showed a linear signal range over three 
orders of magnitude and at 1.0 µg/mL DNA was still in the linear range with sufficient 
fluorescence intensity to achieve an adequate signal window (Fig. 2A).
The development of EndA inhibitors requires the production of active and stable forms of 
EndA for in vitro activity assays. Unfortunately, successful over-expression procedures of 
recombinant wild-type EndA has not been reported to date, presumably due to uncontrolled 
nuclease degradation of the host DNA/RNA. Historically, the enzyme has been expressed as 
an inactive mutant, with the catalytic active site histidine residue replaced with alanine 
(H160A).17, 25 Structure-based modeling suggests that the active site of the EndA variant 
can accommodate a single imidazole molecule in place of the missing histidine sidechain, 
leading to “rescue” of the nuclease activity. Structural information also suggests that the Cβ 
of H160A might present a steric clash with the imidazole, which could be relieved by a 
glycine substitution (H160G) at that position. Consistent with this theory, the EndA(H160G) 
mutant is considerably more active than EndA(H160A).17 We therefore elected to use 
EndA(H160G) for assay development, and imidazole can be considered a cofactor in assays 
measuring the imidazole-dependent nuclease activity of EndA(H160G).26
To determine the optimum concentration of imidazole, the kinetics of 10 mM EndA(H160G) 
catalyzed DNA hydrolysis were measured using the PicoGreen assay at imidazole 
concentrations ranging from 0 to 200 mM (Fig. 2B). The observed enzyme velocity reached 
a maximum at 50 mM imidazole, then decreased at higher concentrations. This inverse 
effect was reported previously with EndA(H160G) and is likely explained by the elevated 
ionic strength of the buffer at high imidazole concentrations.17 An imidazole concentration 
of 25 mM was chosen as the optimal concentration for the PicoGreen assay.
In the presence of 25 mM imidazole and a saturating concentration of Hind III digested 
lambda DNA (1 µg/mL), EndA’s nuclease activity increased monotonically with initial 
EndA concentration (Supplementary Fig. S1). An EndA concentration of 15 nM was 
selected for further experiments because this was the lowest EndA concentration to produce 
approximately linear enzyme activity over a reasonable time range and sufficient dsDNA 
digestion to achieve an adequate signal window. Optimized conditions included 15 nM 
EndA, 1 µg/mL DNA, and 25 mM imidazole. Since EndA has been shown to be a divalent 
metal ion dependent nuclease,25 MgCl2 was added to the reaction at 5 mM. Under these 
conditions at room temperature, the PicoGreen assay demonstrated linear nuclease kinetics 
to 40 min (Supplementary Fig. S2). We elected to use 30 min as the reaction time to remain 
comfortably within the assay’s linear dynamic range.
Another advantage of the PicoGreen assay is its adaptation for real-time monitoring of 
PicoGreen fluorescence changes, as EndA nuclease activity is unaffected by the presence of 
PicoGreen dye (data not shown). This allows kinetic and mechanistic parameters of putative 
inhibitors to be explored using the same assay method.
Given that small-molecule library samples are dissolved in DMSO in preparation for 
screening, the effect of DMSO on EndA activity was investigated at several different DMSO 
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concentrations, up to 10% (vol/vol) (Fig. 2C). There was no significant impact on EndA’s 
observed initial velocity by DMSO up to 1% (vol/vol). At 5% and 10% DMSO, there was an 
apparent increase in EndA activity. This increased activity has been observed with other 
DNA processing enzymes and one likely explanation is that DMSO molecules replace water 
molecules around the DNA, thus increasing the affinity of the enzyme for DNA.27 The final 
DMSO concentration used for screening was 1% (vol/vol).
In other studies, we examined the effect of bovine serum albumin (BSA) and detergent on 
the signal-to-background window of the PicoGreen assay. In screening assays, BSA 
provides an alternative interaction surface for promiscuous small-molecule aggregates and 
detergent disrupts the formation of colloidal aggregates that can nonspecifically inhibit 
enzyme activity.28 The influence of BSA and TritonX-100 were each evaluated over three 
concentration points and no substantial effects were observed on the signal-to-background 
window (Supplementary Fig. S3). To efficiently reduce nonspecific aggregation-based 
inhibition by promiscuous inhibitors, 0.01% TritonX-100 and 1.5 µM BSA were selected as 
final concentrations.
To assess the reproducibility of the PicoGreen assay, a number of test 384-well plates were 
evaluated for interplate and interday variability. Over a span of 3 days, 9 replicate assay 
plates were run under the optimized conditions described above and used to compile the 
mean control signals (Fig 3) for Z′ factor calculation.29 The maximum signal or inhibited 
controls (32 per plate, two columns of a 384-well plate) consisted of wells containing EndA, 
DNA, imidazole and 50 mM EDTA in buffer. The minimum signal controls (32 per plate, 2 
columns of a 384-well plate) consisted of wells containing EndA, DNA, imidazole and 1% 
DMSO in buffer. The PicoGreen reagent was added after 30 min, followed by measurement 
of fluorescent intensity signal using an EnVision plate reader. The average control signals 
for interplate assays performed on the same day were analyzed and used to calculate the Z' 
values of 0.61, 0.63 and 0.64 for each day. Additionally, the interday variability in the 
maximum signal control was less than 10%. Overall, these results are characteristic of a 
high-quality assay suitable for HTS, and Z' values were found to improve with use of liquid 
handling equipment.
Pilot screen of LOPAC library
Using the optimized and validated PicoGreen assay, we screened the Library of 
Pharmacologically Active Compounds (LOPAC) against EndA(H160G) as a pilot screen 
study. The LOPAC contains 1,280 biologically active compounds that were compressed into 
four 384-well plates. The LOPAC was assessed in duplicate for EndA inhibition at a final 
compound concentration of 10 µM. The LOPAC pilot screening results demonstrated a 
normal distribution centered on a mean of 6% inhibition with a standard deviation (SD) of 
8% (Fig 4A). Moreover, the LOPAC pilot screen was characterized by an average Z′ factor 
of 0.87 (Fig. 4B), and demonstrated strong correlation between replicates (Fig. 4C). To 
ensure that we would only identify high-quality hits, we used a selection criterion of > 40% 
inhibition, which represented more than 4 standard deviations away from the minimum 
signal control. As summarized in Table 1, we found 16 primary hits from the LOPAC screen 
and 14 of these compounds were obtained as DMSO stocks for IC50 analysis. In total, 9 of 
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14 compounds were identified as validated hits, and 3 compounds, MK-886 (PubChem CID: 
4519262),30 6-hydroxy-DL-DOPA (PubChem CID: 107794),31 and Myricetin (PubChem 
CID: 5281672)32 had IC50 values in the nanomolar range. Despite their potency against 
EndA, we found these screening hits also inhibited many other non-related enzymes,33 and 
studies suggest they may be aggregate-forming inhibitors.34 While the LOPAC pilot screen 
provided a number of novel biochemical inhibitors of EndA(H160G), the compounds were 
of the promiscuous type and emphasized the need for additional screening. Importantly, 
however, the LOPAC pilot screen validated the PicoGreen assay as a robust and 
reproducible method for high-throughput screening of compound libraries.
Kinase Focus Set Screening
The Kinase Focus Set was selected as the compound collection for our continuing screening 
efforts to identify inhibitors of EndA nuclease activity. The Kinase Focus Set was designed 
at the University of North Carolina at Chapel Hill using a combination of kinase 
pharmacophore-based searching and selection from vendor kinase directed sets. Although 
EndA is not a kinase, the small-molecules of the Kinase Focus Set were of a manageable 
number, represented a diversity of scaffolds, and all were “rule of five” compliant.18 The 
Kinase Focus Set has been routinely screened at UNC using non-kinase targets. Moreover, 
the Kinase Focus Set has yielded selective and potent inhibitors against another nucleic acid-
processing enzyme.35
Compounds from the Kinase Focus Set were screened against EndA in singleton at 10 µM 
from 1 mM DMSO stocks using the PicoGreen assay. The screening results gave a normal 
distribution with a mean of 5% inhibition and a SD of 11% (Figure 5A). Overall, the 
average Z′ = 0.87 for the 16 analyzed plates (Figure 5B). The screen yielded 79 compounds 
with ≥ 40% inhibition (3·σ above the mean) and a 1.7% primary screen hit rate (Table 1). 
We eliminated 2 compounds with unfavorable physiochemical properties and performed 
dose-response analysis of 77 compounds from their 10 mM DMSO stocks from the 
CICBDD. The IC50 measurements for the 77 initial hits were performed in duplicate and 
confirmed 32 compounds as having IC50 ≤ 30 µM, giving a 42% confirmation rate. Further 
evaluation of the confirmed hits revealed 10 compounds having acceptable curve shape by 
visual inspection and a maximum % inhibition greater than 60%. Raw data for duplicate 
runs of a validated hit compound demonstrated reproducible dose-dependent inhibition of 
enzyme activity over the concentrations tested and a mean IC50 = 9 ± 1 µM (Fig. 6).
The EndA screen of the Kinase Focus Set showed a remarkably high confirmed hit rate 
(0.68%). With respect to hit rate, the EndA screen was ranked fourth among 12 screening 
campaigns against the Kinase Focus Set at UNC. The 3 screens that showed higher hit rates 
(between 0.85% and 1.18%) all targeted protein kinases; the 8 other screens with lower hit 
rates were not against kinases. It is unclear why compounds featuring “kinase-like” chemical 
motifs (mainly by mimicking the adenosine moiety of ATP) were so efficient on a target 
lacking a well-defined ligand/co-factor pocket.17 A plausible hypothesis is that prospective 
kinase inhibitors may fortuitously possess a chemical feature that also makes them also 
potent against endonucleases. For instance, most known kinase inhibitors are designed to 
have a common structural fragment called the hinge-binding motif. The hinge-binding motif 
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is a packed set of hydrogen-bond donors and acceptors that bind to a portion of the protein 
backbone connecting the large and small lobes of the kinase domain.36 However, it is 
common for such a motif to also have chelating properties and, hence, may also bind the 
Mg2+ ion present in the EndA catalytic site. Regardless, the overall screening statistics 
indicate a high-quality assay and confirm the utility of the PicoGreen assay to discover 
novel inhibitors of EndA(H160G) by HTS.
Biochemical characterization of validated hits
Of the 10 compounds identified as validated hits, three were available from commercial 
sources. We obtained 4 additional commercially available compounds from the Kinase 
Focus Set that were characterized by IC50 ≤ 30 µM, but with curve shapes that did not meet 
our original criteria for validated compounds. In particular, they were originally 
deprioritized because of steep curve shapes and only one data point after the curve inflection 
point. Nonetheless, due to limited availability of more favorable compounds, they were 
reordered, and freshly prepared at 10 mM in 100% DMSO. We retested the 7 compounds in 
dose-response and performed further assays to better characterize their biochemical activity 
and prioritize them for follow-up microbiological experiments. To counter-screen against 
possible off-target effects, we employed two assays that enabled us to identify false-
positives that were identified due to DNA-binding by the test compounds or assay 
interference. We also tested inhibitors to determine whether binding was reversible. Finally, 
we employed a plasmid conversion nuclease assay17, 25 to confirm inhibition of EndA by an 
orthogonal method.
A compound that binds DNA could produce a false-positive in the PicoGreen assay by 
sequestering the DNA, thereby preventing EndA nuclease activity. To test for DNA binding, 
we employed the real-time PicoGreen nuclease assay in the absence of EndA(H160G) at 
three concentrations (1, 30, 100 µM final) of test compound. True inhibitors of EndA had no 
effect on fluorescence, while compounds that bind DNA or interfere with the DNA-
PicoGreen interaction decreased the fluorescence signal. Only 1 of the 7 compounds showed 
a significant effect in the counter-screen (Supplementary Fig. S4), suggesting that this 
compound may interact with dsDNA. Of the 6 remaining reordered compounds, 
UNC10103486 showed reproducible dose-dependent activity with a micromolar IC50 (Fig. 
7A), no effect in the counter-screen (Fig. 7B) and also no activity in other assays recorded in 
the UNC database. Therefore, we focused our attention on the biochemical characterization 
of compound UNC10103486.
The PicoGreen nuclease assay measured the imidazole-dependent nuclease activity of 
EndA(H160G). Therefore, it was possible that some of the identified compounds inhibited 
the rescued EndA variant by interfering with imidazole binding to the active site. To test 
compound UNC10103486 for an imidazole-dependent mechanism of action, EndA(H160G) 
activity was measured by the real-time PicoGreen nuclease assay as a function of imidazole 
concentration at different inhibitor concentrations. Analysis of the resulting velocity-
imidazole concentration curves revealed that UNC10103486 inhibition was not competitive 
with imidazole (Fig. 7C).
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To determine whether UNC10103486 binding was reversible, we adapted the real-time 
PicoGreen nuclease assay with a rapid dilution assay. Briefly, inhibitor was allowed to bind 
EndA at a concentration expected to inhibit roughly 95% of EndA activity, then diluted to a 
concentration expected to inhibit only 5% of EndA activity. A reversible inhibitor would 
dissociate quickly, allowing immediate recovery of enzyme activity; a slowly reversible 
inhibitor would allow a gradual increase in activity; and an irreversible inhibitor would 
completely prevent the recovery of enzyme activity. Dilution of EndA inhibited by 
UNC10103486 did allow a gradual recovery of EndA, with an initial velocity of 62 ± 22 
counts·min−1, compared to 128 ± 6 counts·min−1 with DMSO alone (Fig. 7D). This 
confirmed a reversible binding mechanism for UNC10103486.
We confirmed the inhibition of EndA by UNC10103486 by an alternative nuclease assay 
that looks at plasmid DNA conversion. In this simple assay, supercoiled plasmid DNA is 
nicked by EndA and transformed into an open circular structure that runs significantly more 
slowly on an agarose gel. Further plasmid cleavage leads to a linear DNA form that migrates 
as a band between the supercoiled and open circular forms. Progressively, more cleavage 
produces oligonucleotides of various sizes, which appear as a “smear” of faster-migrating 
products on the agarose gel. We monitored the DNA products in the presence of 
UNC10103486 and found a dose-dependent inhibition of plasmid DNA cleavage (Fig. 7E). 
EndA inhibition in the plasmid DNA cleavage assay confirmed the activity of 
UNC10103486 and also that its mechanism was independent of the PicoGreen assay 
detection method.
CONCLUSION
To the best of our knowledge, we have established the first reported HTS assay to identify 
compounds that inhibit nuclease activity. Using a nuclease assay based on the differential 
fluorescence output of PicoGreen, we optimized the assay for HTS against an imidazole-
rescued variant EndA(H160G). Following stringent assay validation, including a pilot screen 
of LOPAC, the assay was used to screen 4,727 compounds from the Kinase Focus Set. The 
screen had an average Z' = 0.87 and resulted in the identification of 10 validated hits. From 
these hits, the compound UNC10103486 was confirmed as active in an orthogonal EndA 
nuclease assay and acts via a mechanism independent of PicoGreen and imidazole.
The validation of the PicoGreen nuclease assay and its use in HTS is fundamental to the 
search for nuclease inhibitors. Specifically, drugs that inhibit nuclease activity may help to 
improve the outcome of bacterial infection with Streptococcus pyogenes and Staphylococcus 
aureus, which also express nucleases that facilitate NET evasion.37, 38 Additionally, a major 
advantage of the PicoGreen nuclease assay is its versatility as both a screening assay and for 
monitoring nuclease activity in real-time. Such broad application of this technology allows 
for a consistent transition from primary screening to more in-depth studies of binding 
properties and mechanism of inhibition.
The S. pneumoniae surface endonuclease EndA has at least two functions that are important 
in pneumococcal disease. EndA is responsible for DNA degradation and transport during 
transformation, which contributes to pneumococcal genome variation. Genetic variation, 
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including both de novo adaptation and acquisition of genes conferring antibiotic resistance 
or virulence factors, is important for the persistence of the pathogen and progression of 
disease. In addition, the superficial location of EndA permits extracellular degradation of the 
DNA component of NETs, thereby facilitating pneumococcal dissemination and increasing 
the risk of invasive infection. These activities of EndA contribute to pathogenesis, making 
the pneumococcal nuclease an attractive target for controlling S. pneumoniae diseases. 
Currently, experiments are underway to evaluate UNC10103486 and other promising in 
vitro inhibitors of EndA using live bacteria assays for transformation and NET degradation. 
The facile identification of small-molecule inhibitors is an important first step for 
developing pharmacologic probes of EndA to address its roles in pneumococcal virulence 
and to establish it as a druggable target for combating pneumococcal infection.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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PicoGreen screening assay for discovery of EndA inhibitors. Inhibitors of EndA prevent the 
EndA-mediated degradation of dsDNA. Interaction of PicoGreen with dsDNA results in an 
increased fluorescence over free PicoGreen and PicoGreen interaction with ssDNA and 
short dsDNA fragments.
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Assay optimization with respect to (A) DNA substrate in the presence of PicoGreen (B) 
imidazole, and (C) DMSO tolerance determined in 384-well format. (A) Hind III digested 
lambda DNA in the presence of 0.8 µM PicoGreen. (B) Scatter plot of EndA reaction initial 
velocity in the presence of various amounts of imidazole. (C) Bar graph depicting initial 
velocities of EndA reaction in the presence of various amounts of DMSO. The data 
presented are mean ± SD of triplicate wells (n = 3).
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Assay validation over multiple plates and multiple days. The 384-well plates were divided 
into 32 wells of minimum signal (gray circles) and 32 wells of maximum signal (black 
signal) control reactions. The variation was measured between three individual runs on the 
same day and the variation between runs on three separate days. Without using liquid 
handling system, the overall Z' for 96 wells on days 1, 2, and 3 were 0.61, 0.63, and 0.64, 
respectively.
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Results from the LOPAC pilot screen. (A) Frequency distribution of the LOPAC pilot 
screen relative inhibition results depicted as a histogram, where the number of compounds in 
each bin (±1% width) is plotted on a log scale. (B) Z' factor analysis of the 8 plates assayed 
during LOPAC pilot screen in duplicate. 32 wells of minimum controls (0.1% v/v DMSO 
final) and 32 wells of maximum activity controls (50 mM EDTA final) were used to 
calculate the Z' factor. Dashed line indicates the average Z' = 0.87. (C) Correlation plot of 
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the relative inhibition from duplicate runs of EndA LOPAC screen with solid line indicating 
perfect 1:1 correlation.
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Kinase Focus Set HTS results. (A) Frequency distribution of Kinase Focus Set relative 
inhibition results depicted as a histogram, where the number of compounds in each bin (±1% 
width) is plotted on a linear scale. (B) Plot of the Z' factors from the 16 plates assayed 
during Kinase Focus Set HTS. The average Z' = 0.87 and is represented by the dashed line.
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Reproducible concentration-response measurements of a validated compound from the 
Kinase Focus Set screen. The calculated IC50 = 9 ± 1 µM was reproducible for duplicate 
runs: n = 1 (○) and n = 2 (□).
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Biochemical characterization of a promising EndA inhibitor. (A) The IC50 = 17 µM for 
compound UNC10103486 was calculated from the average of duplicate runs. (B) Results of 
EndA enzyme absent counter-screen displays normal F counts in the presence of compound 
UNC10103486. (C) Compound UNC10103486 is non-competitive with respect to 
imidazole. (D) Initial velocities from rapid dilution reversibility test suggest compound 
UNC10103486 is a reversible inhibitor of EndA. (E) Plasmid DNA conversion EndA(160G) 
assay timecourse in the absence or presence of 30 µM UNC10103486. Timepoints were 
taken at 10 sec, 30 sec, 1 min, 2 min, 5 min, 10 min, 15 min and 20 min. Lane M contains 
molecular markers comprsing 1 kb DNA ladder and lane P is untreated pBluescript II SK(+) 
plasmid. The migration of supercoiled (sc), open circular (oc) and linear molecules is 
indicated by markers on the right-hand side.
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Table 1
Summary of HTS for EndA Inhibitors
Primary Screen Summary LOPAC Kinase Set
Number of compounds tested 1,280 4,727
Overall primary screen hit rate (%) 1.3 1.7
Number of hits* 16 79
IC50 Confirmation Summary LOPAC Kinase Set
Number of compounds tested 14 77
Overall hit rate (%) 0.70 0.68
Number of IC50 confirmed* hits 9 32
Validation rate (%) 57 13
Number of validated* hits 8 10
*
Compounds with >40% Inhibition (3·σ above the mean)
*
Compounds with IC50 ≤ 30 µM
**
Compounds with IC50 ≤ 30 µM, max % inhibition ≥ 60%, and acceptable curve shape by visual inspection.
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